Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This study found that among prostate cancer patients undergoing a biopsy, those with metabolic syndrome tended to have a lower Gleason score compared to those without the syndrome.

Finasteride may reduce prostate cancer risk.

This article discusses the documented benefits of finasteride for managing benign prostatic hyperplasia, noting the need for monitoring due to its effects on serum PSA levels; it reports no adverse impact on prostate cancer detection.

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.